Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 6:37 AM ET


Company Overview of Kolltan Pharmaceuticals, Inc.

Company Overview

Kolltan Pharmaceuticals, Inc. discovers and develops novel antibody-based drugs targeting receptor tyrosine kinases (RTK) for the treatment of cancer and other diseases. Its lead product candidate includes KTN3379, an antibody targeting the ErbB3 RTK, which is in Phase I clinical trials for adult patients with advanced solid tumors. The company is also developing KTN0158, a KIT RTK inhibitor for the treatment of neurofibromatosis type 1 and other inflammatory diseases; and KIT-ADC, an antibody drug conjugate for oncology treatment, as well as a range of research programs targeting RTKs. Kolltan Pharmaceuticals, Inc. was founded in 2007 and is based in New Haven, Connecticut.

300 George Street

Suite 530

New Haven, CT 06511

United States

Founded in 2007

37 Employees





Key Executives for Kolltan Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 60
Co-Founder and Chairman of the Board
Age: 50
Co-Founder, Chairman of Scientific Advisory Board, Chief Scientist and Director
Age: 70
Chief Financial & Business Officer and Senior Vice President
Age: 49
Senior Vice President of Translational Medicine & Product Development
Age: 49
Compensation as of Fiscal Year 2015.

Kolltan Pharmaceuticals, Inc. Key Developments

Kolltan Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2015, Nov-18-2015 02:15 PM

Kolltan Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2015, Nov-18-2015 02:15 PM. Venue: The New York Palace Hotel, Hubbard Room, New York, New York, United States. Speakers: Gerald McMahon, Chief Executive Officer, President and Director.

Kolltan Pharmaceuticals, Inc. Presents at Boston Biotech Conferences 2015, Nov-12-2015 02:30 PM

Kolltan Pharmaceuticals, Inc. Presents at Boston Biotech Conferences 2015, Nov-12-2015 02:30 PM. Venue: Apella, 450 East 29th Street, NY 10016, New York, United States.

Kolltan Pharmaceuticals Appoints Ronald A. Peck as Chief Medical Officer and Senior Vice President, Clinical Development

Kolltan Pharmaceuticals, Inc. announced the appointment of Ronald A. Peck, M.D., as Chief Medical Officer and Senior Vice President, Clinical Development. Dr. Peck will lead the clinical development of Kolltan’s product pipeline and will report to President and Chief Executive Officer Gerald McMahon, Ph.D. Dr. Peck will succeed Carolyn F. Sidor, M.D., who will continue as a medical and regulatory consultant to the company. Dr. Peck has over 15 years of extensive drug development expertise in oncology and other areas. Prior to joining Kolltan, Dr. Peck held roles of increasing responsibility at Bristol-Myers Squibb Company since 2000, where he contributed to the successful development of multiple therapeutic drug products.

Similar Private Companies By Industry

Company Name Region
Bio-Research Products, Inc. United States
Neurotech Pharmaceuticals, Inc. United States
BioProcessing, Inc. United States
MakuCell, Inc. United States
Matrix Genetics United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Kolltan Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at